These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 10980629)

  • 1. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.
    Zinzani PL; Magagnoli M; Bendandi M; Tani M; Stefoni V; Cellini C; Poggi S; Piccioli M; Pileri S; Tura S
    Haematologica; 2000 Sep; 85(9):922-5. PubMed ID: 10980629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine.
    Zinzani PL; Tani M; Marchi E; Stefoni V; Alinari L; Musuraca G; Gabriele A; Pileri S; Baccarani M
    Haematologica; 2004 Mar; 89(3):309-13. PubMed ID: 15020269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
    Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
    Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
    Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
    Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five day intermittent vs seven day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia.
    Damasio EE; Resegotti L; Masoudi B; Bruni R; Cerri R; Isaza A; Clavio M; Risso M; Rossi E; Spriano M; Truini M
    Recenti Prog Med; 1998 Feb; 89(2):68-73. PubMed ID: 9558908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
    Else M; Dearden CE; Matutes E; Garcia-Talavera J; Rohatiner AZ; Johnson SA; O'Connor NT; Haynes A; Osuji N; Forconi F; Lauria F; Catovsky D
    Br J Haematol; 2009 Jun; 145(6):733-40. PubMed ID: 19344416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hairy-cell leukemia and alpha-interferon treatment: long-term responders.
    Zinzani PL; Lauria F; Salvucci M; Rondelli D; Raspadori D; Bendandi M; Magagnoli M; Tura S
    Haematologica; 1997; 82(2):152-5. PubMed ID: 9175317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
    Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
    Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
    Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
    Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
    Kong LR; Huang CF; Hakimian D; Variakojis D; Klein L; Kuzel TM; Gordon LI; Zanzig C; Wollins E; Tallman MS
    Cancer; 1998 Mar; 82(5):957-64. PubMed ID: 9486587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
    Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Subcutaneous therapy of hairy cell leukemia with 2-chlorodeoxyadenosine].
    Nielsen OJ; Hippe E; Priø TK; Juliusson G
    Ugeskr Laeger; 1994 Apr; 156(16):2407-9. PubMed ID: 7912015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of 34 cases of hairy cell leukemia treated with interferon-alpha and/or 2-chlorodeoxyadenosine.
    Zaja F; Fanin R; Silvestri F; Russo D; Infanti L; Baccarani M
    Haematologica; 1997; 82(4):468-70. PubMed ID: 9299866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
    Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
    Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.
    Else M; Ruchlemer R; Osuji N; Del Giudice I; Matutes E; Woodman A; Wotherspoon A; Swansbury J; Dearden C; Catovsky D
    Cancer; 2005 Dec; 104(11):2442-8. PubMed ID: 16245328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
    Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
    Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
    Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
    Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience.
    Chadha P; Rademaker AW; Mendiratta P; Kim B; Evanchuk DM; Hakimian D; Peterson LC; Tallman MS
    Blood; 2005 Jul; 106(1):241-6. PubMed ID: 15761021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia.
    Krykowski E; Warzocha K; Robak T
    Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):317-21. PubMed ID: 8744653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-CdA in the treatment of hairy cell leukaemia.
    Abhyankar D; Bajpai S; Saikia T; Gopal R; Nair CN; Advani SH
    J Assoc Physicians India; 2001 Aug; 49():785-7. PubMed ID: 11837464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.